US Drug Recall Register
Class I · High risk Terminated Initiated Dec 15, 2021 (5 years ago)

Clobetasol Propionate Ointment USP

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Microbial Contamination of Non-Sterile Products: presence of R. Pickettii bacteria

What was recalled

Clobetasol Propionate Ointment USP, 0.05%, 60g tubes, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. NDC 51672-1259-3

Recalling firm
Taro Pharmaceuticals U.S.A., Inc.
NDC code
51672-1259-3
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0375-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Clobetasol recalls

See all
Class II · Moderate risk Ongoing

Clobetasol Propionate Shampoo

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0796-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Ointment

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0795-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Cream

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0794-2023
Class III · Low risk Terminated

Clobetasol propionate Cream USP

Reason Subpotent Drug: Low assay result observed during long-term stability testing.

Lupin Pharmaceuticals Inc. NDC 68180-956-03 D-0174-2023
Class II · Moderate risk Terminated

Clobetasol Propionate Lotion 0.05%

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Preferred Pharmaceuticals, Inc. NDC 68788-7768-01 D-0768-2022